WallStSmart

Alibaba Group Holding Ltd (BABA)vsBrilliA Inc (BRIA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alibaba Group Holding Ltd generates 2133016% more annual revenue ($1.04T vs $48.99M). BABA leads profitability with a 7.0% profit margin vs -0.0%. BABA earns a higher WallStSmart Score of 55/100 (C-).

BABA

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 8.0Quality: 6.5
Piotroski: 2/9Altman Z: 2.02

BRIA

Avoid

24

out of 100

Grade: F

Growth: 2.0Profit: 4.0Value: 5.0Quality: 7.5
Piotroski: 1/9Altman Z: 3.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BABAUndervalued (+58.1%)

Margin of Safety

+58.1%

Fair Value

$363.49

Current Price

$113.24

$250.25 discount

UndervaluedFair: $363.49Overvalued

Intrinsic value data unavailable for BRIA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BABA4 strengths · Avg: 8.8/10
Market CapQuality
$281.47B10/10

Mega-cap, among the largest globally

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.528/10

Growing faster than its price suggests

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

BRIA3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
3.5210/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

BABA4 concerns · Avg: 3.3/10
P/E RatioValuation
25.6x4/10

Moderate valuation

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Profit MarginProfitability
7.0%3/10

7.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

BRIA4 concerns · Avg: 2.5/10
Market CapQuality
$36.00M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Revenue GrowthGrowth
-34.0%2/10

Revenue declined 34.0%

EPS GrowthGrowth
-96.4%2/10

Earnings declined 96.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : BABA

The strongest argument for BABA centers on Market Cap, Debt/Equity, PEG Ratio. PEG of 0.52 suggests the stock is reasonably priced for its growth.

Bull Case : BRIA

The strongest argument for BRIA centers on Altman Z-Score, Debt/Equity, Price/Book.

Bear Case : BABA

The primary concerns for BABA are P/E Ratio, Return on Equity, Profit Margin.

Bear Case : BRIA

The primary concerns for BRIA are Market Cap, Piotroski F-Score, Revenue Growth.

Key Dynamics to Monitor

BABA profiles as a value stock while BRIA is a turnaround play — different risk/reward profiles.

BABA is growing revenue faster at 8.6% — sustainability is the question.

BRIA generates stronger free cash flow (257,000), providing more financial flexibility.

Monitor INTERNET RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BABA scores higher overall (55/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alibaba Group Holding Ltd

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Alibaba Group Holding Limited, also known as Alibaba Group and Alibaba.com, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via web portals, as well as electronic payment services, shopping search engines and cloud computing services. It owns and operates a diverse portfolio of companies around the world in numerous business sectors.

BrilliA Inc

CONSUMER CYCLICAL · APPAREL RETAIL · USA

BrilliA Inc. is an innovative biotechnology company dedicated to enhancing skin health and advancing regenerative medicine through cutting-edge solutions for wound healing. By harnessing proprietary technologies, BrilliA addresses significant unmet medical needs, aiming to improve patient quality of life. With a strong commitment to research and development, the company is well-positioned to transform scientific advancements into effective therapeutic products, solidifying its role as a leader in the dynamic healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?